TNF α signaling beholds thalidomide saga: a review of mechanistic role of TNF-α signaling under thalidomide
- PMID: 22650377
- DOI: 10.2174/156802612801784443
TNF α signaling beholds thalidomide saga: a review of mechanistic role of TNF-α signaling under thalidomide
Abstract
Tumor necrosis factor alpha (TNF-α) is a pleiotropic inflammatory cytokine. The cytokine possesses both growth stimulating properties and growth inhibitory processes, and it appears to have self regulatory properties as well. Agents like etanercept and infliximab showed beneficial effects against rheumatoid arthritis by modulationg TNF-α proteins, however, these agents are largely unable to penetrate the blood-brain barrier, which severely limits their use in different conditions. Thalidomide, an inhibitor of TNF-α protein synthesis is readily capable of crossing the blood-brain barrier and thus thalidomide and its analogs are excellent candidates for use in determining the potential value of anti-TNF-α therapies in a variety of diseases. Thalidomide blocks TNF-α expression by different possible mechanisms. Down regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), an essential transcription factor for TNF and other cytokines under thalidomide treatment leads to reduction in the TNF-α expression. Additionally, myeloid differentiation factor 88 (MyD88), an adapter protein regulates the expression of TNF under thalidomide treatment. Thalidomide treatment also leads to destruction of TNF-α mRNA thus, reducing the total expression of TNF-α protein. Thalidomide also targets reactive oxygen species (ROS) and α(1)-acid glycoprotein (AGP) to regulate TNF-α. In the present review, we discuss different possible mechanism that regulates TNF-α under thalidomide treatment. Additionally, we suggest novel strategies for the future targeting combination therapies of thalidomide and its analogs with different other anti-inflammatory drug to curb TNF-α associated diseases.
Similar articles
-
Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression.Innate Immun. 2009 Feb;15(1):33-41. doi: 10.1177/1753425908099317. Innate Immun. 2009. PMID: 19201823
-
Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways.Photodermatol Photoimmunol Photomed. 2003 Dec;19(6):272-80. doi: 10.1046/j.1600-0781.2003.00055.x. Photodermatol Photoimmunol Photomed. 2003. PMID: 14617101
-
TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.Curr Alzheimer Res. 2007 Sep;4(4):378-85. doi: 10.2174/156720507781788873. Curr Alzheimer Res. 2007. PMID: 17908040 Review.
-
Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester.J Immunol. 2002 Mar 15;168(6):2644-51. doi: 10.4049/jimmunol.168.6.2644. J Immunol. 2002. PMID: 11884428
-
Transcending conventional therapies: the role of biologic and other novel therapies.Inflamm Bowel Dis. 2001 May;7 Suppl 1:S9-16. doi: 10.1002/ibd.3780070504. Inflamm Bowel Dis. 2001. PMID: 11380043 Review.
Cited by
-
Effectiveness of thalidomide for ankylosing spondylitis: a meta-analysis of randomized controlled trials in China.Clin Rheumatol. 2022 Oct;41(10):2929-2938. doi: 10.1007/s10067-022-06220-0. Epub 2022 May 30. Clin Rheumatol. 2022. PMID: 35635651 Review.
-
Cancer drugs with high repositioning potential for Alzheimer's disease.Expert Opin Emerg Drugs. 2023 Dec;28(4):311-332. doi: 10.1080/14728214.2023.2296079. Epub 2023 Dec 26. Expert Opin Emerg Drugs. 2023. PMID: 38100555 Free PMC article. Review.
-
Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.Front Immunol. 2018 Mar 26;9:594. doi: 10.3389/fimmu.2018.00594. eCollection 2018. Front Immunol. 2018. PMID: 29632537 Free PMC article. Review.
-
Antiangiogenic therapy for primitive neuroectodermal tumor with thalidomide: A case report and review of literature.Medicine (Baltimore). 2017 Dec;96(51):e9272. doi: 10.1097/MD.0000000000009272. Medicine (Baltimore). 2017. PMID: 29390485 Free PMC article. Review.
-
Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy.Pharmaceutics. 2023 Mar 27;15(4):1074. doi: 10.3390/pharmaceutics15041074. Pharmaceutics. 2023. PMID: 37111560 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources